An induction therapy
1.1 is recommended before surgery or kidney transplant surgery begins combination of immunosuppressive drugs .
1.2 is recommended to use the biological agents into induction therapy in renal transplant recipients (Kidney Transplant Recipient, KTR) initial free Fuzhou General Hospital of Nanjing Military Region, Department of Urology, Zheng Kai
Immunosuppressive programs.
1.2.1 Recommended interleukin 2 receptor antagonist (IL2Ra) as first-line induction therapy medication .
1.2.2 For a high risk of rejection in renal transplant recipients , it is recommended not to use anti-lymphocyte preparations interleukin 2 receptor antagonist.
2 Initial maintenance phase of immunosuppressive drugs
2.1 Recommended maintenance therapy in combination with immunosuppressants including calcineurin inhibitors (CNI) and anti-proliferative drugs, or does not contain
Sugar corticosteroids .
2.2 recommends the CNI tacrolimus as first-line treatment .
2.2.1 is recommended before surgery or kidney transplantation began using tacrolimus or cyclosporine A (CsA), rather than wait until the beginning of graft function
Recovery began to use . (2D tacrolimus ; 2B cyclosporine A)
2.3 is recommended that mycophenolate antiproliferative drugs as first-line treatment .
2.4 for low -risk patients and excluded patients received induction therapy , 1 week after transplantation is recommended to stop the use of corticosteroids .
2.5 To use the mammalian target of rapamycin inhibitors (mTORi), recommended full recovery of renal function in transplant surgery wound healing
After use .
3 long-term maintenance phase of immunosuppressive drugs
3.1 Failure of acute rejection after transplantation proposal within two to four months using the lowest maintenance dose of immunosuppressive drugs.
3.2 recommends continued use of CNI, rather than withdrawal.
3.3 If the transplant is still in use prednisone week recommended the continued use rather than withdrawal.
没有评论:
发表评论